×

Substantial uncertainty with Valeant: Analyst

5:16 PM ET Fri, 4 March 2016

Dimitry Khmelnitsky, Veritas Investment research analyst, sticks with a sell rating for Valeant Pharmaceuticals and explains why the stock is not invest worthy.